Tebotelimab, a PD1/LAG-3 bispecific antibody, in patients with untreated, unresectable, recurrent or metastatic, mucosal melanoma: An open-label, single-arm, Phase 1 study

被引：0
|
作者：
Lu, Si
Chen, Yu
Fang, Meiyu
Zou, Zhengyun
Wu, Di
Luo, Zhiguo
Zhang, Jian
Chen, Jing
Huang, Gang
Pan, Hongming
Ren, Xiubao
Cheng, Ying
Su, Haichuan
Xin, Yuan
Hua, Qiong
Hou, Jianmei
Guo, Jun
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 08期
关键词：
D O I：
10.1158/1538-7445.AM2023-CT208
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT208
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Anti-PD-1 antibody SHR-1210 plus apatinib for metastatic colorectal cancer: a prospective, single-arm, open-label, phase II trial
    Ren, Chao
    Mai, Zong-Jiong
    Jin, Ying
    He, Ming-Ming
    Wang, Zhi-Qiang
    Luo, Hui-Yan
    Zhang, Dong-Sheng
    Wu, Chen-Yi
    Wang, Feng
    Xu, Rui-Hua
    AMERICAN JOURNAL OF CANCER RESEARCH, 2020, 10 (09): : 2946 - +
  • [32] PD-1 antibody camrelizumab for Epstein-Barr virus-positive metastatic gastric cancer: a single-arm, open-label, phase 2 trial
    Sun, Yu-Ting
    Guan, Wen-Long
    Zhao, Qi
    Wang, De-Shen
    Lu, Shi-Xun
    He, Cai-Yun
    Chen, Shuang-Zhen
    Wang, Feng-Hua
    Li, Yu-Hong
    Zhou, Zhi-Wei
    Xu, Rui-Hua
    Qiu, Miao-Zhen
    AMERICAN JOURNAL OF CANCER RESEARCH, 2021, 11 (10): : 5006 - +
  • [33] COMBINATION OF NIRAPARIB AND ANLOTINIB IN PATIENTS WITH RECURRENT OR METASTATIC ENDOMETRIAL CANCER: AN OPEN-LABEL, SINGLE-ARM, TWO-STAGE, PHASE II STUDY
    Ren, Yulan
    Lu, Jing
    Tian, Wenjuan
    Li, Haiming
    Wang, Huaying
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 : A107 - A107
  • [34] Safety and anti-tumor activity of Pasireotide in patients with BRAF- and NRAS-wild type, unresectable and or metastatic melanoma: a phase I, open-label, single-arm study
    Schadendorf, D.
    Michielin, O.
    Nageli, M.
    Goldinger, S. M.
    Campigotto, F.
    Kriemler-Krahn, U.
    Schmid, H. A.
    Pedroncelli, A. M.
    Micaletto, S.
    Dummer, R.
    MELANOMA RESEARCH, 2016, 26 : E43 - E44
  • [35] A single-arm, open-label, phase. study investigating anti-HER2 ADC plus anti-PD-1 antibody in patients with unresectable locally advanced or metastatic BTC with HER2 overexpression.
    Chen, Xiaofeng
    Guo, Fen
    Zhang, Xinyi
    Qiu, Jinrong
    Zheng, Tongsen
    Qiu, Hong
    Tian, Yitong
    Pan, Lanlan
    Zhang, Jiaguang
    Chen, Yizhang
    Shen, Haoyang
    Wang, Chao
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : TPS619 - TPS619
  • [36] ALMB-0168, a novel Cx43 hemichannel agonist monoclonal antibody, for metastatic or unresectable osteosarcoma after standard chemotherapy: A multicenter, open-label, single-arm, phase 1 study
    Shen, Jingnan
    Guo, Wei
    Wang, Jin
    Xie, Xianbiao
    Xie, Lu
    Xu, Jie
    Jing, Chen
    Lin, Jianhua
    Li, Xianan
    Zhou, Yong
    Wang, Guowen
    Zhang, Xiaojing
    Yao, Weitao
    Dong, Yang
    Ye, Zhaoming
    Wang, Li
    Zeng, Yanyan
    Wu, Yongyong
    Yang, Xiugao
    Zhang, Yanfeng
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [37] An open-label, single arm, phase II trial of niraparib in combination with anti-PD1 antibody in recurrent/advanced stage endometrial cancer patients
    Li, J.
    Wei, W.
    ANNALS OF ONCOLOGY, 2021, 32 : S772 - S772
  • [38] An open-label, single-arm, dose escalation and expansion phase 1 study of tebotelimab (MGD013) plus niraparib in patients with locally advanced or metastatic gastric cancer who failed prior treatments.
    Qiu, Miaozhen
    Pan, Hongming
    Lam, Ka On
    Wang, Jufeng
    Zheng, Yi
    Luo, Huiyan
    Zheng, Yu
    Zhen, Xiaoa
    Hang, Wenzhao
    Hou, Jianmei
    Xu, Rui-hua
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 402 - 402
  • [39] A multicenter, single-arm, open-label phase II study to evaluate the efficacy and safety of YH003 in combination with pembrolizumab and nab-paclitaxel in the first-line treatment of patients with unresectable/metastatic mucosal melanoma
    Chen, Yu
    Zhang, Xiaoshi
    Ding, Ya
    Jiang, Yu
    Chen, Jing
    Pu, Xingxiang
    Ren, Xiubao
    Zhang, Weizhen
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [40] Safety and efficacy of azilsartan in paediatric patients with hypertension: a phase 3, single-arm, open-label, prospective study
    Shuichi Ito
    Yuya Nishiyama
    Kenkichi Sugiura
    Kazuaki Enya
    Clinical and Experimental Nephrology, 2022, 26 : 350 - 358
12345